TWO Clearbridge Health units are being sued by a unit's shareholder for damages of 1.06 trillion rupiah (S$102 million) relating to a notarial deed, the company said in a bourse filing on Sunday...

CATALIST-LISTED Clearbridge Health will be a non-exclusive regional distributor of its Catalist-listed spin-off Biolidics’ coronavirus antibody test kits, according to bourse filings.

CLEARBRIDGE Health on Thursday night said it does not know of any unannounced information which might explain the jump in its share price earlier in the day.

COVID COUNTERS

SHARES of Biolidics rapidly lost the bulk of their gains accumulated from recent days, after the medtech firm announced that Nasdaq-listed Aytu Bioscience will be the exclusive distributor of its...

SINGAPORE'S healthcare plays, in particular medical-supply stocks, rallied on Wednesday even as the benchmark Straits Times Index fell 0.07 per cent to 2,550.04. This came as the number of...

CANCER diagnostics firm Biolidics on Wednesday evening said it is in the final stages of negotiations with a potential distributor for the sale of its Covid-19 rapid test kits in the US.

CANCER-diagnostics company Biolidics has entered an agreement to acquire Biomedics Laboratory from SAM Laboratory, a subsidiary of Clearbridge Health, for a cash consideration of up to S$3.7...

CATALIST-LISTED Clearbridge Health said on Monday that it looks to raise S$11.34 million through various subscription agreements for 80.5 million placement shares at S$0.141 apiece.

CATALIST-listed Clearbridge Health will build a new 1,500 square foot clinic in Causeway Bay, Hong Kong to better cater to both domestic patients and medical tourists, the company announced in a...

THE following companies saw new developments that may affect trading of their shares on Monday: